Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides

In Vivo

Volumn 26, Issue 4, 2012, Pages 609-618

  Segatori, Valeria I ^a   Otero, Laura L ^a   Fernandez, Luis Enrique ^b   Gomez, Daniel E ^a   Alonso, Daniel F ^a   Gabri, Mariano R ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer; Cytidine monophospho N acetylneuraminic acid hydroxylase; Immunotherapy; N glycolylated gangliosides; Sialic acid

Indexed keywords

CANCER VACCINE; GANGLIOSIDE GM3; IMMUNOLOGICAL ADJUVANT; MESSENGER RNA; N GLYCOLOYLNEURAMINIC ACID; UNCLASSIFIED DRUG; VERY SMALL SIZE PROTEOLIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CARCINOGENICITY; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; CYTIDINE MONOPHOSPHO N ACETYLNEURAMINIC ACID HYDROXYLASE GENE; DRUG ACTIVITY; ENZYME MECHANISM; GENE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOLECULAR CLONING; MOUSE; NONHUMAN;

EID: 84865083141     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jazirehi AR, Huerta-Yepez S, Cheng G and Bonavida B: Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65: 264-276, 2005. (Pubitemid 40070818)
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M and Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
3. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM and Matrisian LM: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337, 2009.
4. Ravindranath MH, Hsueh, EC, Verma M, Ye W and Morton DL: Serum total ganglioside level correlates with clinical course in melanoma patients after immunotherapy with therapeutic cancer vaccine. J Immunother 26: 277-285, 2003. (Pubitemid 36686896)
5. Kavanagh D, Hill AD, Djikstra B, Kennelly R, McDermott EM and O'Higgins NJ: Adjuvant therapies in the treatment of stage II and III malignant melanoma. Surgeon 3: 245-256, 2005. (Pubitemid 41051551)
6. Gabri MR, Mazorra Z, Ripoll GV, Mesa C, Fernandez LE, Gomez DE and Alonso DF: Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model. Clin Cancer Res 12: 7092-7098, 2006. (Pubitemid 44974509)
7. Alonso DF, Gabri MR, Guthmann MD, Fainboim L and Gomez D: A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Int J Oncol 15: 59-66, 1999.
8. Torréns I, Mendoza O, Batte A, Reyes O, Fernández LE, Mesa C and Guillén G: Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine 23: 5768-5774, 2005.
9. Mesa C, De León J, Rigley K and Fernández LE: Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 22: 3045-3052, 2004. (Pubitemid 39037206)
10. Mesa C, de León J, Rigley K and Fernández LE: Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for dendritic cell activation. Vaccine Suppl 2: 42-43, 2006.
11. Fernández A, Mesa C, Marigo I, Dolcetti L, Clavell M, Oliver L, Fernández LE and Bronte V: Inhibition of tumor-induced myeloid-derived suppressor cell function by nanoparticulated adjuvant. J Immunol 186: 264-274, 2011.
12. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, Rengifo E, Pérez R and Fernández LE: A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19: 241-247, 2000. (Pubitemid 30622625)
13. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R and Ando S: Gangliosides expressed in human breast cancer. Cancer Res 56: 5165-5171, 1996. (Pubitemid 26383031)
14. Gabri MR, Otero LL, Gomez DE and Alonso DF: Exogenous incorporation of Neugc-rich mucin augments N-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. J Exp Clin Cancer Res 28: 146, 2009.
15. Shaw L and Schauer R: The biosynthesis of N-glycoloylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid. Biol Chem Hoppe Seyler 369: 477-486, 1988.
16. Rodríguez M, Llanes L, Pérez A, Pérez R and Vázquez AM: Generation and characterization of an anti-idiotype monoclonal antibody related to GM3 (NeuGc) ganglioside. Hybrid Hybridomics 22: 307-314, 2003.
17. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR and Eccles SA; Committee of the National Cancer Research Institute: Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577, 2010.
18. Estevez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, Sierra GV and Fernandez LE: Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 18: 190-197, 1999. (Pubitemid 29432152)
19. Carr A, Mazorra Z, Alonso DF, Mesa C, Valiente O, Gomez DE, Perez R and Fernandez LE: A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res 11: 219-227, 2001. (Pubitemid 32578808)
20. Birklé S, Zeng G, Gao L, Yu RK and Aubry J: Role of tumor-associated gangliosides in cancer progression. Biochimie 85: 455-63, 2003.
21. Hakomori S: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res 56: 5309-5318, 1996.
22. Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Pérez K, Rodríguez JL, Barroso Mdel C, Hernández AM, Toledo D, Gabri MR, Alonso DF, Viada C, Gómez RE, Suárez E, Vazquez AM, Perez R and Macias AE: 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 6: 1847-1852, 2007.
23. Durrant LG, Noble P and Spendlove I: Immunology in the Clinic Review Series; Focus on cancer: Glycolipids as targets for tumour immunotherapy. Clin Exp Immunol 167: 206-215, 2012.
24. Heimburg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A and Rittenhouse-Olson K: Cancer vaccines and carbohydrate epitopes. Vaccine 29: 8802-8826, 2011.
25. Hevey R and Ling CC: Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies. Future Med Chem 4: 545-584, 2012.
26. Blanco R, Rengifo E, Cedeño M, Rengifo CE, Alonso DF and Carr A: Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System. ISRN Gastroenterol 645641, 2011.
27. Deng W, Li R and Ladisch S: Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 92: 912-917, 2000. (Pubitemid 30429191)
28. Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM and Gullino PM: Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res 47: 4243-4247, 1987. (Pubitemid 17124310)
29. Ladisch S: Tumor cell gangliosides. Adv Pediatr 34: 45-58, 1987.
30. Ladisch S, Kitada S and Hays EF: Gangliosides shed by tumor cells enhance tumor formation in mice. J Clin Invest 79: 1879-1882, 1987.
31. Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky C and Seeger R: Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 39: 73-76, 1987. (Pubitemid 17233830)
32. Yanina N, Malykh, Roland Schauer and Lee Shaw: N-Glycolylneuraminic acid in human tumours. Biochimie 83: 623-34, 2001.
33. Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, Gomez DE and Alonso DF: NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol 2010: 814397, 2010.
34. Labrada M, Clavell M, Bebelagua Y, León J, Alonso DF, Gabri MR, Veloso RC, Vérez V and Fernández LE: Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther 10: 153-162, 2010.
35. Koyama S, Yamaji T, Takematsu H, Kawano T, Kozutsumi Y, Suzuki A and Kawasaki T: A naturally occurring 46-amino acid deletion of Cytidine monophospho-N-acetylneuraminic acid hydroxylase leads to a change in the intracellular distribution of the protein. Glycoconj J 13: 353-358, 1996.
36. Altheide TK, Hayakawa T, Mikkelsen TS, Diaz S, Varki N and Varki A: System-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents: Evidence for two modes of rapid evolution. J Biol Chem 281: 25689-25702, 2006. (Pubitemid 44401958)
37. Prinetti A, Aureli M, Illuzzi G, Prioni S, Nocco V, Scandroglio F, Gagliano N, Tredici G, Rodriguez-Menendez V, Chigorno V and Sonnino S: GM3 synthase overexpression results in reduced cell motility and in caveolin-1 up regulation in human ovarian carcinoma cells. Glycobiology 20: 62-77, 2010.
38. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD and Giaccone G: Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 9: 180, 2009.
39. Scursoni AM, Galluzzo L, Camarero S, Pozzo N, Gabri MR, de Acosta CM, Vázquez AM, Alonso DF and de Dávila MT: Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry. Pediatr Dev Pathol 13: 18-23, 2010.
40. Scursoni AM, Galluzzo L, Camarero S, Lopez J, Lubieniecki F, Sampor C, Segatori VI, Gabri MR, Alonso DF, Chantada G and de Dávila MT: Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. Clin Dev Immunol 2011: 245181, 2011.